文献速递外周动脉疾病

逆行腘动脉入路治疗股腘动脉闭塞性疾病

Retrograde popliteal access to treat femoropopliteal artery occlusive disease.
PubMed 文献 · J Vasc Surg · 2018-03-01

基于血管质量倡议(VQI)2010至2016年数据,比较逆行腘动脉(RPA)入路与顺行股总动脉(CFA)入路治疗股腘动脉病变的安全性和有效性。RPA入路技术成功率显著低于CFA入路(80.4% vs 93.8%;P < .001),6个月免于主要不良肢体事件(MALE)生存率和通畅率也显著降低,但围手术期并发症和30天死亡率无差异。多因素分析显示RPA入路与原发性通畅率丢失独立相关(HR 1.91;95%CI 1.24-2.94;P = .003)。作者认为当CFA入路无法完成时可考虑该技术。

要点

  • RPA入路技术成功率显著低于CFA入路(80.4% vs 93.8%;P < .001)。
  • RPA入路6个月免于MALE生存率(74.5% vs 83.5%;P = .016)和通畅率(70.3% vs 83.1%;P < .001)显著低于CFA入路。
  • 多因素分析显示RPA入路与原发性通畅率丢失独立相关(HR 1.91;95%CI 1.24-2.94;P = .003)。

核心结论

  • RPA入路与顺行入路相比,6个月技术成功率和原发性通畅率较低。
  • 两种入路技术在围手术期并发症、30天死亡率及6个月截肢、MALE和生存方面无差异。
  • 作者认为当CFA入路无法完成时可考虑该技术。

研究设计与样本

  • 基于血管质量倡议(VQI)数据库的回顾性分析,纳入2010至2016年因症状性外周动脉疾病接受RPA入路的患者,并与标准CFA入路比较。
  • 排除急性肢体缺血患者,分析术前、术中、术后数据及围手术期和6个月结局。
  • 共纳入30,074例孤立性股浅动脉和腘动脉病变患者,其中148例接受RPA入路。

主要发现

  • 总体适应证包括间歇性跛行(56.3%)、静息痛(13.9%)和组织缺损(29.8%)。
  • RPA入路技术成功率显著低于CFA入路(80.4% vs 93.8%;P < .001)。
  • RPA入路与CFA入路在动脉夹层(8.3% vs 6.3%;P = .333)、远端栓塞(0% vs 1.2%;P = .183)、穿刺点血肿(3.4% vs 3.1%;P = .849)和30天死亡率(1.4% vs 1.1%;P = .789)方面相似。
  • RPA入路组6个月免于MALE生存率(74.5% vs 83.5%;P = .016)和通畅率(70.3% vs 83.1%;P < .001)显著低于CFA入路组。

临床怎么用

  • 作者认为当CFA入路无法完成时可考虑RPA入路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Retrograde popliteal artery (RPA) access to treat superficial femoral artery and popliteal artery disease is an option when treatment through common femoral artery (CFA) access is not possible. Our goal was to compare the safety and efficacy of RPA access with CFA access for treatment of femoral and popliteal artery lesions. METHODS: The Vascular Quality Initiative was queried for all patients undergoing RPA access from 2010 to 2016 for symptomatic peripheral arterial disease. These were compared with standard CFA access. Patients with acute limb ischemia were excluded. Preoperative, operative, and postoperative data were analyzed. Perioperative and 6-month outcomes were analyzed. Multivariable analysis was used to assess the effect of RPA access on amputation or death, major adverse limb event (MALE) or death, patency, and death. RESULTS: There were 30,074 patients with isolated superficial femoral and popliteal artery disease treated, 148 of whom had RPA access. Indications overall included claudication (56.3%), rest pain (13.9%), and tissue loss (29.8%). RPA access had a significantly lower rate of technical success compared with CFA access (80.4% vs 93.8%; P < .001). RPA access and CFA access were similar for rates of arterial dissection (8.3% vs 6.3%; P = .333), distal embolization (0% vs 1.2%; P = .183), access site hematoma (3.4% vs 3.1%; P = .849), and 30-day mortality (1.4% vs 1.1%; P = .789). There were no differences between RPA access and CFA access for unadjusted 6-month amputation-free survival (94.8% vs 96%; P = .747) or survival (934.3% vs 95.6%; P = .845). MALE-free survival (74.5% vs 83.5%; P = .016) and patency (70.3% vs 83.1%; P < .001) were significantly lower in the RPA access group. Multivariable analysis showed no differences between patients who were successfully treated by RPA access and CFA access for amputation-free survival (hazard ratio [HR], 1.24; 95% confidence interval [CI], 0.46-3.32; P = .669), MALE-free survival (HR, 1.57; 95% CI, 0.99-2.5; P = .057), and survival (HR, 0.86; 95% CI, 0.43-1.73; P = .675). RPA access was independently associated with loss of primary patency (HR, 1.91; 95% CI, 1.24-2.94; P = .003). CONCLUSIONS: RPA access had lower technical success and primary patency compared with antegrade access at 6 months. There were no differences demonstrated between the two access techniques in perioperative morbidity and mortality or 6-month amputation, MALE, and survival. This technique should be considered when CFA access cannot be accomplished.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Komshian S, Cheng TW, Farber A, et al. Retrograde popliteal access to treat femoropopliteal artery occlusive disease. J Vasc Surg. 2018. PMID: 29503002. doi:10.1016/j.jvs.2017.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。